Inicio>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Talampanel

Talampanel (Synonyms: GYKI 53773, LY 300164)

Catalog No.GC19346

Talampanel (LY300164) es un antagonis oral y selectivo del receptor de α-amino-3-hidroxi-5-metil-4-isoxazolpropionato (AMPA) con actividad anticonvulsiva.

Products are for research use only. Not for human use. We do not sell to patients.

Talampanel Chemical Structure

Cas No.: 161832-65-1

Tamaño Precio Disponibilidad Cantidad
5mg
62,00 $
Disponible
10mg
93,00 $
Disponible
50mg
324,00 $
Disponible
100mg
508,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED). Target: AMPA [1]in vitro: Talampanel is a glutamate receptor inhibitor with anti-seizure activity.in vivo: Talampanel reduces motoneuronal calcium in a mouse model of ALS, but its effi cacy declines as the disease progresses, suggesting that medication initiation in the earlier stages of the disease might be more effective. [2]

References:
[1]. Langan YM, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003 Jan;44(1):46-53.
[2]. Paizs M, et al. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph Lateral Scler. 2011 Sep;12(5):340-344.

Reseñas

Review for Talampanel

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Talampanel

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.